Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00583-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Thomas Maitre und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Paris, France. Hauptthemen laut MEDLINE: Levofloxacin, Mycobacterium tuberculosis, Microbial Sensitivity Tests, Mice, Inbred BALB C. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
High-dose levofloxacin was explored in a clinical trial against multidrug-resistant tuberculosis and failed to show increased efficacy. In this study, we used a murine model to explore the efficacy of a dose increase in levofloxacin monotherapy beyond the maximum dose evaluated in humans. A total of 120 4-week-old female BALB/c mice were intravenously infected with 10 6 CFU of Mycobacterium tuberculosis H37Rv wild-type (WT) or isogenic H37Rv mutants harboring GyrA A90V or D94G substitutions; the MICs were 0.25, 4, and 6 µg/mL, respectively. Levofloxacin 250 and 500 mg/kg were given every 12 h (q12h) orally for 4 weeks. Pharmacokinetic parameters were determined after five doses. These two regimens decreased lung bacillary load in mice infected with H37Rv WT but not in mice infected with the A90V and D94G mutants. Levofloxacin 250 mg/kg q12h in mice generated pharmacokinetic parameters equivalent to 1,000 mg/d in humans, whereas 500 mg/kg q12h generated a twofold greater exposure than the highest equivalent dose tested in humans (1,500 mg/d). In our dose–response model, the effective concentration at 50% (EC 50 ) produced an AUC/MIC (AUC 0–24h /MIC) ratio of 167.9 ± 27.5, and at EC 80 it was 281.2 ± 97.3. Based on this model, high-dose levofloxacin regimens above 1,000 mg/d are not expected to cause a significant increase in bactericidal activity. This study suggests no benefit of high-dose levofloxacin above 1,000 mg/d in the treatment of fluoroquinolone-susceptible or -resistant tuberculosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Paris, France.
- Department of Pneumology and Reference Centre for Rare Lung Diseases, Assistance Publique Hôpitaux de Paris, Tenon Hospital, Paris, France.
- Fédération de Bactériologie, Centre National de Référence des Mycobactéries, APHP, Sorbonne Université, Paris, France.
- Unité de Microbiologie Clinique et Dosage des Anti-infectieux, Groupe Hospitalier Paris-Saint-Joseph, Paris, France.
ORCID-Profile: Thomas Maitre
Zitieren
APA
Maitre, T., Godmer, A., Mory, C., Chauffour, A., Mai, T. C., El Helali, N., Aubry, A., & Veziris, N. (2024). Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00583-24
Vancouver
Maitre T, Godmer A, Mory C, Chauffour A, Mai TC, El Helali N, et al. Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00583-24
BibTeX
@article{Maitre2024,
author = {Maitre, Thomas and Godmer, Alexandre and Mory, Céline and Chauffour, Aurélie and Mai, Thi Cuc and El Helali, Najoua and Aubry, Alexandra and Veziris, Nicolas},
title = {Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00583-24}
}
EUVIMED